Introduction
The replication of the causative pathogen of the acquired immunodeficiency syndrome (AIDS). the human immune-deficiency virus-1 (HIV-1), can be inhibited by interfering with the function of virally encoded enzymes or structural components required for virus replication. One class of prominent anti-AIDS compounds inhibits the HIV-1 encoded reverse transcriptase (Rl); in their triphosphate forms some nucleoside analogues e.g. 3'-azido-2',3'dideoxythymidine (AZl) (Mitsuya and Broder. 1987) or 3'-fluoro-2' ,3'-dideoxythymidine (FddThd) (Matthes et aI., 1989) inhibit this enzyme in a competitive manner. Other compounds have been identified which abolish the function of HIV-1 regulatory gene products. One of those agents is pyronin Y, an RNA intercalating drug (Darzynkiewicz et al., 1986) ,which prevents binding of Rev protein of HIV-1 to Rev-responsive element (RRE)-containing env RNA in vitro (Schroder et aI., 1990b) . Another promising way for a therapeutic intervention is to suppress expression of viral genes by antisense oligonucleotides (ODN). Goodchild et al. (1988) and Daum et al. (1992) have demonstrated that antisense ODN directed against the splice acceptor site of the exon II of the regulatory gene tat blocks the splicing process leading to functional 2-kb tat mRNA.
A further promising and rationally-designed therapy for HIV infection is based on the augmentation of physiological antiviral and cellularly encoded defence systems. It has been shown that the dsRNA-dependent 2',5' -oligoadenylate [2-5A] synthetase/RNase L system is involved in the establishment of the antiviral state of cells (Schroder et el., 1992) . The activity of the 2-5A synthetase(s) (Chebath et al., 1987) is dependent on the presence of synthetic and naturally occurring dsRNA or RNA stem-loop structures, e.g. of heterogeneous nuclear RNA or the TAR RNA sequence of HIV-1 (Schroder et aI., 1990b) . The 2-5A synthetase is induced by treatment of cells with interferon (Nilsen et aI., 1982) and catalyzes the synthesis of 2'-5'-linked oligoadenylate residues (n = 2-4). These mediators act as allosteric activators of RNase L (Silverman et al., 1988) which hydrolyze single-stranded RNA, resulting in degradation of viral and cellular mRNA (Baglioni et al., 1978; Schroder et al., 1989) . Infection of H9 cells with HIV-1 causes a transitory increase in 2-5A synthetase and RNAse L activity (Schroder et al., 1989) . Subsequently a rapid s: phosphorothioate linkage FddThd. FddThd was cytotoxic at 1.64 J.1M but displayed at a 300-fold lower concentration its 50% cytoprotective effect on HIV-1 infected cells (Table 1) . (Table 1) . Also the nonsense ODN (# 5) did not show any anti-HIV activity.
The non-modified ODN-1 as well as the antisense ODN which was modified at the 3'-terminus (ODN-2) by two phosphorothioate linkages was ineffective as anti-HIV-1 compound (Fig. 1) . In contrast, the ODNs which were modified either at their 5' -terminus only (ODN-3)or both at the 3'-and 5' -terminus by two phosphorothioates (ODN-4) displayed an anti-HIV activity in infected Molt-3 cells. Quantitative analyses revealed that the inhibitory potency of ODN-4, which was modified at its two ends, was the highest; the antiviral activity (EC so ) was determined to be 0.30 [1M. In a control experiment nonsense 20-mer (ODN-5)was tested and found not to inhibit virus growth in HIV-1 infected Molt-3 cells below concentrations of 2.5 [1M ( Fig. 1 sense antisense:
Results
Anti-HIVactivity (cytoprotection assay) of poly(lj'poly(C 12U), antisense oligonucleotides, FddThd and pyronin Yin HIV-1/Molt-3 cells decrease of both enzyme activities occurs, simultaneous with the rise in viral protein synthesis (Schroder et aI., 1989) . The time period until onset of HIV-1 production can be extended in vitro by 2-5A analogues (MOiler et al., 1988; Montefiori et aI., 1989; Suhadolnik et al., 1989) interferon (Ho et al., 1985) or mismatched dsRNA . Transfection experiments using the 2-5A synthetase gene under the control of HIV-1 LTR revealed that the transfected cells become resistant against HIV-1 infection due '(0 the Tat-TAR-mediated expression of the synthetase after HIV-1 infection (Schroder et aI., 1990a) . This experiment demonstrates also that stimulation of the 2-5A synthetase/RNase L pathway effectively prevents HIV-1 production.
The expression of 2-5A synthetase can be induced by treatment of cells with synthetic dsRNA such as poly(l)'poly(C); in addition the latter polymer activates also 2-5A syntethase (Ilson et et., 1986) . Due to its cytotoxicity (Krown et aI., 1983) the applicability of poly(I)·poly(C) is limited. The toxicity of this dsRNA could be abolished by introduction of non-hydrogen-bonded uracil residues into the poly(C)strand at periodic distances (Nilsen et al., 1982; Carter et aI., 1987) . Hence, this mismatched dsRNA, poly(I)'poly(C 12U) also termed Ampligen, exhibits immunomodulatory, antitumour (Strayer et aI., 1986) , and antiviral activities (Mitchell et aI., 1987; in vitro. Moreover, clinical trials revealed an enhancement of both T-and B-cell immunity and decline in HIV load in patients treated with poly(I)·poly(C 12U) Strayer et al., 1991) .
In the present study we investigated whether stimulation of the physiologically functioning antiviral protection system (2-5A synthetase/RNase L) by the mismatched dsRNA, poly(I)'poly(C 12U) [Ampligen], causes an augmentation of the anti-HIV-1 effects displayed by inhibitors of RT (we selected as an example FddThd, that compound which had been studied in our groups extensively [Matthes et al., 1989] ) and the viral regulatory proteins Tat and Rev (antisenseODN and pyronin Y) in vitro. The results show synergy in all combinations with poly(I)·poly(C 12U).
Poly(lj·poly(C 12U). The mismatched dsRNA, poly(l)'poly(C 12U) [Ampligen], was not toxic for Molt-3 cells at concentrations below 100 [1g rnr'. Dose-response experiments with HIV-1 infected Molt-3 cells revealed that at a concentration of 9.7 [1g rnl" the virus-caused reduction of growth rate was abolished by 50% (Table 1) .
Pyronin Y. As reported earlier for the CEM/HIV-IJI B (Schroder et aI., 1993) and now confirmed also for the Molt-3/HIV-1J1B system, pyronin Y given alone showed after an incubation period of 7 days no antiviral but only a cytotoxic effect (TC so : 2.2 [1M; Table 1 ). ae. 20 Table 2 . Effect of poly(I)'poly(C'2U), antisense ODN-4 and FddThd on releaseof HIV-l from infected Molt-3 cells. The RT activity was determined in the supernatants 7 days poslinfection; the data are given as per cent of inhibition of RT activity, compared to the infected controls. In addition, the values for the inhibition of HIV-l protein p17 and p24 expression are shown. As a control, the growth rate of uninfected cells is set atl 00%. The means of five parallel experiments are given. The SD does not exceed 15%. ODN-4 ( Fig. 2) , FddThd (Fig. 3 ) and pyronin Y (Fig. 4) . This enzyme degrades viral mRNA locally (Schroder et aI., 1990a) . The latter function of poly(I)'poly(C 12U) is assumed to cause the anti-HIV effect .
In this report we studied the anti-HIV-1 activity caused by the immunomodulator, poly(I)'poly(C 12U) [effect on the cellular 2-SA synthetase/RNase L system], in combination with inhibitors of RT and of the regulatory proteins Tat and Rev [effects on viral systems]. The inhibitory potencies of the compounds if added alone to HIV-1 infected Molt-3 cells in vitro confirmed earlier data. Under the conditions used poly(l)'poly(C 12U) reduced virus formation at a concentration of 9.7 fL9 ml-1; in an earlier report the antiviral activity (C3-HTLV-IIIB; CEM-HTLV-IIIB) was measured at 1Q-SOfL9 rnr' ). In our system FddThd displayed an anti-HIV activity at 2.4nM, and hence was similarly active as in MT-4-HTLV-IIIB cells [3 nM] (Matthes et sl., 1989) . The antisense ODN-4 reduced virus growth in the Molt-3-HTLV-IIIB system at 0.3 fLM; the same concentration was active in CEM-HTLV-IIIB cells (Daum et sl., 1992) . Pyronin Y alone displayed no specific antiviral activity neither in CEM-HTLV-IIIB cultures (Schroder et sl., 1993) nor in Molt~3-HTLV-IIIB cells (presented data), after an incubation period of 7 days. Given in combination, our results show that poly(I)'poly(C 12U) potentiates the antiviral activities of (1) the RT inhibitor FddThd, (2) the inhibitor of tat gene expression, the The exact FIC values for the combination poly(I)'poly (C12U):pyronin Y could not be evaluated because individually, pyronin Y did not display an antiviral effect; its value is close to 0 (Table 1) .
Discussion
Immunomodulators may be classified into naturally occurring mediators, e.g. cytokines Or synthetic organic molecules, An example of these is (1) thiocarbamate that modulates the response of immune competent cells through a signal transduction mechanism resulting in a differential gene expression and (2) substances that stimulate the physiologically existing antiviral protection system of cells, the 2-SA synthetase/RNase L pathway.
Compounds that belong to the latter class are the polynucleotides, poly(l)'poly(C) (Carter et al., 1974) and poly(l) ·poly(C 12U) . They display two functions; firstly they induce interferon and secondly they activate the 2-SA synthetase/RNase L system resulting in the synthesis of 2-SA which in turn activates the RNase L. antisense ODN-4 (modified by 5'-and 3'-end capped thioates) and (3)the RNA-intercalating agent pyronin Y.
The results reported here show a ranking order of potencies of the combinations with poly(I)'poly(C12U): pyronin Y > FddThd > antisense ODN-4. Interestingly pyronin Y added in combination also synergized the antiviral effect of poly(l)·poly(C 12U). Due to the high cytotoxicity pyronin Y added alone to the HIV-1 infected cells was without antiviral activity. Pyronin Y is an intercalating cationic dye that binds specifically to dsRNA and condensed single-stranded RNA (Darzynkiewicz et aI., 1986) . The underlying, molecular mechanism for the potentiating effect of pyronin Y on the antiviral effect of poly(I)'poly(C 12U) is not known. In view of earlier findings we assume that pyronin Y may intercalate into poly(I)·poly(C 12U) (Darzynkiewicz et aI., 1986) and in turn stabilizes the latter compound. In first studies with 32P-labelled poly(I)'poly(C 12U) we found that if this dsRNA is bound to pyronin Y its stability in the culture medium increased almost 1O-fold(to be published). Furthermore in a previous study Jamison et al. (1990) reported that neither intercalating agents, e.g. ethidium bromide or adriamycin alone, nor poly(A-U) were efficient antiviral agents. However, if the intercalating agents were combined with poly(A-U) a strong antiviral activity was measured in the vesicular
Cells and virus infection
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and pyron in Y were obtained from Sigma (St. Louis, MO).
Mismatched dsRNA (poly(I)·poly(C 12U), Ampligen, was provided by HEM Research (Philadelphia, PAl. Its average molecular weight was determined to be 5 ± 1 x 1OS [laser light scattering] (R. J. Suhadolnik, personal communication) . 2',3'-Oideoxy-3'-fluorothymidine (FddThd) was obtained as described (Matthes et al., 1989) .
Materials and Experimental procedures

Materials
The T-Iymphoblastoid Molt-3 cells (ATCC CRL 1552) were infected with HIV-1 (strain HTLV IIIB ) ; 100 times the 50%-cell culture infective dose [CCIO so ; 1 CCIOso belnq the dose infective for 50% of the cell cultures] per ml of cell suspension was used (Muller et al., 1988 (Muller et al., , 1991 . The cells were grown in RPMI 1640 medium supplemented with 15% (vlv) fetal calf serum; cultures were maintained at 3rC in a humidified 5% CO2 in air atmosphere (Muller et al., 1988). stomatitis virus system without affecting the interferon production. The authors suggest that the polynucleotide together with the intercalating dyes directly activate the interferon response genes, which are known to maintain the antiviral state (Lammers et al., 1988) .
Pyronin Y, the compound which prevents binding of Rev protein to the HIV-1 RRE element in vitro (Schroder et al., 1993) , should be considered as a lead compound for less toxic anti-Rev compounds which could also be applied in vivo. Likewise, the in vivo therapeutical usefulness of antisense ODN is not yet proven (Mirabelli et al., 1991) . However, the two other compounds studied here, poly(l) 'poly(C 12U) [Ampligen] (Carter et aI., 1987) and FddThd (8. Polsky et aI., personal communication), showed already promising anti-AIDS activity in clinical trials. The results presented here provide the rationale to combine in future clinical anti-AIDS trials immunomodulators which augment the natural antiviral defence system, e.g. poly(I)·poly(C 12U), with anti-HIV-1 compounds which are directed against the viral enzyme (R1) or viral regulatory proteins. However, for a further decision if such a combination is warranted, the immunosuppressive potential of the compound to be administered together with the immunemodulator in a combination trial must be known. Especially from the nucleoside analogues, e.g. AZT, it is known that they toxically affect bone marrow progenitor cells (Sommadossi and Carlisle, 1987) .
We suggest, that immunomodulators rniqht be beneficial also in a combination therapy to restore the damage of the immune system caused by immunosuppressive anti-AIDS drugs. 
Cytotoxicity studies
In the presence of different concentrations of poly(I),poly(C 12U) 1 x 10 s cells mr ' of uninfected Molt-3 cells were incubated in 16-mm culture wells (Costar) for 1 day. Then the cells were infected with HIV-1; 3 h later the different compounds (FddThd, antisense ODN or pyronin Y) were added at the indicated concentrations. The viability of the cells was monitored by the MIT colorimetric assay system (Scudiero et al., 1988) after an incubation period of 7 days.
The cytotoxic effects displayed by the compounds were measured in cultures with uninfected Molt-3 cells. The values causing a 50% decrease of cell concentration (compared to the controls) -the 50% cytotoxicity concentrations (TCso) -were calculated by logarithmic reqresslon (Sachs, 1984) .
Analysis of results
Cytoprotection assay. Again the viability of the cells was monitored by the MIT test. The 50% effective antiviral concentrations (EC so ) represent those concentrations at which growth of HIV-infected reached 50% of the growth rate of the uninfected cells during the incubation period of 7 days. The values were estimated from six different test concentrations by logarithmic regression (Sachs, 1984) .
Applying the colorimetric assay system, dose-response curves for a pair of the compounds, alone and in combination, were plotted to determine those concentrations required for 50% inhibition of cytopathic effect of the virus. The concentrations of each drug, alone and in combination, required to achieve 50% inhibition of cytopathicity were then compared with isobolograms (Elion et al., 1954; MOiler and Zahn, 1979) to determine the particular type of interaction. The fractional inhibitory index (FIG) was determined as described (Phillips and Warren, 1976) ; additive effects: FIC = 1, antagonism: FIC>1, synergism: FIC<1.
Determination of p17, p24 and RT. The percentage of persistently infected cells expressing p17 and p24 gag proteins of HIV-1 was determined by indirect immunofluorescence microscopy with the use of mouse monoclonal antibodies to HIV-1 p17 and p24. Positive cells were visualized by treatment with fluoresceinlabelled goat anti-mouse IgG (Sarin et al., 1987) ; the reactivity of the antibodies with HIV-1 infected cells was in the range of 70-85%. For testing of virus release, cells were removed by centrifugation and the supernatant was assayed for RT activity (MOileret al., 1988) ; the activity of this enzyme after an incubation of the infected cells for 7 days was 9.3 x 1Q s cpm rnl' culture fluid.
Oligodeoxynucleotide
The antisense ODN (termed ODN-1) against the splice acceptor site of tat [nucleotide no. 5349 to 5368; according to the nomenclature of Ratner et al. (1985) ] was chosen; the sequence 5'-CCATITICAG covered the intron and the segment 5'-AAITGGGTGTwas in the second exon of tat. The description of the syntheses of the ODN, modified by phosphorothioate linkages has been given earlier (Engels et al., 1991; Daum et el., 1992) . The sequences of the antisense ODNs are given in Fig. 1 . The molecular weights of the ODNs are as follows: ODN-1 and ODN-5, 8017 (counter ion: triethylammonium); ODN-2 and 8081. 
